Comments on: The Vytorin Limbo: Have Scrips Hit Bottom? http://www.pharmalot.com/2008/11/the-vytorin-limbo-have-scrips-hit-bottom/ News, Comment and Conversation Fri, 10 Feb 2012 19:36:51 +0000 http://wordpress.org/?v=2.6.2 By: Dan A. http://www.pharmalot.com/2008/11/the-vytorin-limbo-have-scrips-hit-bottom/#comment-381513 Dan A. Sat, 15 Nov 2008 01:03:09 +0000 http://www.pharmalot.com/?p=17671#comment-381513 With statins as a class of medications- in combination with others, or otherwise: A.E.s are believed to be often under-reported with high doses of potent statins in particular. Additionally, there is no reduction in mortality or increase in the lifespan of one on statin therapy. So caution should perhaps be considered if one chooses to prescribe such a drug. Several risk factors should determine if one is placed on statin therapy, and not just one. Statins do decrease CV events and risks significantly. The statins do in fact increase endothelial function, stabilize coronary plaque build- up, and decrease thrombus formation. Maximum reduction in LDL is evaluated after about a month of therapy. There is evidence to suggest that statins have other benefits besides lowering LDL, such as reducing inflammation (CRP), those with dementia or Parkinson's disease, and some forms of Cancer and cataracts. It appears those statins produced by fermentation, such as Zocor and Pravachol, have less myopathy than the other synthetic statins, possibly due to being more hydrophyllic. Yet overall, the existing cholesterol lowering recommendation should be re-evaluated, as they may be over-exaggerated. Finally, a focus on children and their lifestyles should be amplified so their arteries do not become those of one who is middle-aged, and prevent them from being candidates for statin therapy, Dan Abshear With statins as a class of medications- in combination with others, or otherwise:
A.E.s are believed to be often under-reported with high doses of potent statins in particular. Additionally, there is no reduction in mortality or increase in the lifespan of one on statin therapy. So caution should perhaps be considered if one chooses to prescribe such a drug.
Several risk factors should determine if one is placed on statin therapy, and not just one.
Statins do decrease CV events and risks significantly. The statins do in fact increase endothelial function, stabilize coronary plaque build- up, and decrease thrombus formation. Maximum reduction in LDL is evaluated after about a month of therapy.
There is evidence to suggest that statins have other benefits besides lowering LDL, such as reducing inflammation (CRP), those with dementia or Parkinson’s disease, and some forms of Cancer and cataracts.
It appears those statins produced by fermentation, such as Zocor and Pravachol, have less myopathy than the other synthetic statins, possibly due to being more hydrophyllic.
Yet overall, the existing cholesterol lowering recommendation should be re-evaluated, as they may be over-exaggerated.
Finally, a focus on children and their lifestyles should be amplified so their arteries do not become those of one who is middle-aged, and prevent them from being candidates for statin therapy,

Dan Abshear

]]>